Golixitinib is an oral, highly selective JAK1 inhibitor that may have therapeutic effects on peripheral T-cell lymphoma by inhibiting the JAK/STAT pathway. Golixitinib was approved for marketing in China in June 2024.

Density	1.38 ± 0.1g/cm3 (Predicted)
Storage conditions	Storeat -20 ° C
Solubility	soluble in DMSO
Form	Solid
acidity coefficient (pKa)	14.63 ± 0.30 (Predicted)
Color	light yellow to yellow
InChIKey	CVCVOSPChemicalbookZEVINRM-QEIABERDNA-N
SMILES	N(C1C=CC=C2C(C3C=CN=C(NC4=CN(C)N=C4OC)N=3)=CNC=12)C(=O)[C@H](N1CCN(C)CC1)C|&1:27,r|